March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Systemic And Ocular Adverse Events After 334 Injections Of Intravitreal Bevacizumab In The Treatment Of ROP: Five-Year Follow-Up In 3 Centers
Author Affiliations & Notes
  • Maria A. Martinez-Castellanos
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico, Mexico
  • Lihteh Wu
    Vitreoretinal, Instituto De Cirugia Ocular, San Jose, Costa Rica
  • Fernando Schoonewolff
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico, Mexico
  • Alay Banker
    Retina and Vitreous, Retina clinic and laser center, Ahmedabad, India
  • Rohan Chauhan
    Retina and Vitreous, retina clinic and laser center, Ahmedabad, India
  • Andres Kychenthal
    Retina and Vitreous, Kychenthal Medicos Asociados, Santiago, Chile
  • Paola Dorta
    Retina and Vitreous, Kychenthal Medicos Asociados, Santiago, Chile
  • Virgilio Morales-Canton
    Retina, Asociación para Evitar la Ceguera, Mexico, Mexico
  • Robison V. Chan
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center, Denver, Colorado
  • Footnotes
    Commercial Relationships  Maria A. Martinez-Castellanos, None; Lihteh Wu, None; Fernando Schoonewolff, None; Alay Banker, None; Rohan Chauhan, None; Andres Kychenthal, None; Paola Dorta, None; Virgilio Morales-Canton, None; Robison V. Chan, None; Hugo Quiroz-Mercado, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4684. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria A. Martinez-Castellanos, Lihteh Wu, Fernando Schoonewolff, Alay Banker, Rohan Chauhan, Andres Kychenthal, Paola Dorta, Virgilio Morales-Canton, Robison V. Chan, Hugo Quiroz-Mercado; Systemic And Ocular Adverse Events After 334 Injections Of Intravitreal Bevacizumab In The Treatment Of ROP: Five-Year Follow-Up In 3 Centers. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4684.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe the adverse events of intravitreal bevacizumab (IB) in the treatment of ROP.

Methods: : Analysis of 334 patients treated with IB for ROP during a 5-year period in 3 centers (Asociación para Evitar la Ceguera en México, Mexico, City, Banker's Retina Clinic and Laser Center, Ahmebadad, India, Kychenthal Medicos Asociados, Santiago, Chile). Adverse events after treatment were collected. Follow-up was at least 3 months.

Results: : We had a total of 68 local adverse events (20.35%), which include: worsening of the retinal detachment (1.19%), elevation of IOP (6.88%), peripheral fibrous avascular membrane (1.79%), vitreous hemorrhage (1.79%), and avascular periphery (4.19%). There were no direct systemic adverse events reported. However, 3 patients expired secondary to causes not related to IB treatment. Twenty two (6.5%) patients had some degree of psychomotor developmental retardation.

Conclusions: : After 5 years of follow up, IB appears to be safe for ROP, with treatable ocular adverse events. Systemic abnormalities may be sequelae of prematurity itself and not related to the medication. Longer follow-up is needed.

Clinical Trial: : http://www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • vascular endothelial growth factor • retinal development 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×